RxDoctor Payments Data

Niv Ad

Takoma Park, MDNPI 1982673364

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $756,381 of the $894,220 with a category attached, or 84.6%. Pulse Biosciences, Inc. accounts for 67.8% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $516,457, more than ten times the $30,403 reported in 2019.

$894,220in general payments, 2019–2025

Across 302 payments — averaging $2960.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulse Biosciences, Inc.$606K
  • Atricure, Inc.$225K
  • Helios Cardio Inc$38K
  • Vascular Graft Solutions Inc$20K
  • Medtronic$3K
  • LSI Solutions Inc$719
  • plus $1K from 11 others
$210,096in research payments, 2019–2025

Across 57 payments — averaging $3685.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Atricure, Inc.$131K
  • Livanova USA, Inc.$64K
  • Abbott$16K

What the payments were for

  • Consulting fees$756,38185%
  • Speaking & faculty fees$2,0000%
  • Travel & lodging$129,60814%
  • Food & beverage$6,0561%
  • Education$1740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →